½ÃÀ庸°í¼­
»óǰÄÚµå
1561540

¼¼°èÀÇ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå º¸°í¼­ : À¯Çüº°, Á¦Ç° À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)

Medical Cyclotron Market Report by Type (Ring Cyclotron, Azimuthally Varying Field Cyclotron), Product Type, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 147 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â 2¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 4¾ï 5,340¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2024³âºÎÅÍ 2032³â±îÁö 7.6%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¾Ï ¹ßº´·ü Áõ°¡, ¹æ»ç¼ºÀǾàǰÀÇ ¹ßÀü, ¾çÀüÀÚ¹æ»ç¼±´ÜÃþÃÔ¿µ(PET) ½ºÄµ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ±â¼ú Çõ½Å, ÀÇ·á ÀÎÇÁ¶ó È®´ë, ¿¬±¸ Ȱµ¿ Áõ°¡, ÇÙÀÇÇÐ ¹× ¿µ»óÁø´ÜÀ» ÃËÁøÇÏ´Â Á¤ºÎ Áö¿ø ÀÌ´Ï¼ÅÆ¼ºê µîÀÌ ½ÃÀå ¼ºÀåÀ» °­È­ÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈ÷°í ÀÖ½À´Ï´Ù.

ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ºÐ¼® :

  • ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ: PET, ´ÜÀϱ¤ÀÚ¹æ»ç¼± ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(SPECT)°ú °°Àº ÷´Ü ¿µ»óÁø´Ü¿¡ ÇÊ¿äÇÑ ¹æ»ç¼º µ¿À§¿ø¼Ò¸¦ »ý»êÇϱâ À§ÇÑ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð¿¡ ´ëÇÑ ¼ö¿ä¿Í Àü ¼¼°è ¾Ï ¹× ¸¸¼ºÁúȯÀÇ ±Þ°ÝÇÑ Áõ°¡°¡ °áÇÕÇÏ¿© ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² »çÀÌŬ·ÎÆ®·ÐÀÇ ¼³°è¿Í È¿À²¼º¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀ¸·Î »ý»ê ´É·ÂÀÌ Çâ»óµÇ°í ¿î¿µ ºñ¿ëÀÌ Àý°¨µÇ¸é¼­ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
  • ÁÖ¿ä ½ÃÀå µ¿Çâ : ÁÖ¿ä ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå µ¿ÇâÀ¸·Î´Â ½Å±Ô È­ÇÕ¹° °³¹ß, ÀΰøÁö´É(AI) žÀç µî ¹æ»ç¼ºÀǾàǰ ºÐ¾ßÀÇ ¹ßÀüÀÌ ÀÖÀ¸¸ç, ÀÌ´Â Ä¡·á È¿°ú¿Í Áø´Ü Á¤È®µµ¸¦ Çâ»ó½ÃŰ°í °í¼º´É »çÀÌŬ·ÎÆ®·Ð¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀÔ´Ï´Ù.
  • Áö¸®Àû µ¿Çâ : ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹, ÀϺ», Àεµ¿Í °°Àº ±¹°¡¿¡¼­ źźÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ ¼ºÀå, ¸·´ëÇÑ Á¤ºÎ ÅõÀÚ, ¸¸¼º ÁúȯÀÇ ³ôÀº À¯º´·ü·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ºÏ¹Ì¿Í À¯·´Àº ¼±ÁøÈ­µÈ ÀÇ·á ½Ã½ºÅÛ, °­·ÂÇÑ R&D Ȱµ¿, ÁÖ¿ä »çÀÌŬ·ÎÆ®·Ð Á¦Á¶¾÷üÀÇ Á¸Àç·Î ÀÎÇØ »ó´çÇÑ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
  • °æÀï ȯ°æ: ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð »ê¾÷ÀÇ ÁÖ¿ä ½ÃÀå ±â¾÷À¸·Î´Â Advanced Cyclotron Systems Inc. RadioPharma Solutions, Ionetix Corporation, Isosolution Inc., Siemens AG, Sumitomo Heavy Machinery Industry Corporation, Varian Medical Systems Inc. µîÀÌ ÀÖ½À´Ï´Ù.
  • °úÁ¦ ¹× ±âȸ: »çÀÌŬ·ÎÆ®·Ð ¼³Ä¡ ¹× ¿î¿µ¿¡ ´ëÇÑ ³ôÀº Ãʱ⠺ñ¿ë°ú º¹ÀâÇÑ ±ÔÁ¦ ¿ä°ÇÀº ½ÃÀå ÁøÀÔ ¹× È®Àå¿¡ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ¹Ý¸é, ÇÑÁ¤µÈ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇØ ÈÞ´ë¿ë Àúºñ¿ë »çÀÌŬ·ÎÆ®·Ð ¸ðµ¨¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ºñÁî´Ï½º ±âȸ·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î ¹æ»ç¼ºÀǾàǰÀÇ °³¹ß°ú Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó »çÀÌŬ·ÎÆ®·Ð Á¦Á¶¾÷üµéÀÌ Çõ½ÅÀûÀÎ Á¦Ç°À» °³¹ß ¹× È®ÀåÇÏ´Â µ¥ ÀÖ¾î Å« ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå µ¿Çâ :

¾Ï°ú ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡

ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå Á¶»ç º¸°í¼­¿¡ µû¸£¸é ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä µ¿Çâ Áß Çϳª´Â Àü ¼¼°è ¾Ï ¹× ±âŸ ¸¸¼º ÁúȯÀÇ ÀÌȯÀ² Áõ°¡ÀÔ´Ï´Ù. ¾ÏÀº ¿©ÀüÈ÷ ¼¼°è ÁÖ¿ä »ç¸Á ¿øÀÎ Áß ÇϳªÀ̸ç Á¶±â ¹ß°ß ¹× Ä¡·á¸¦ À§ÇÑ Ã·´Ü Áø´Ü µµ±¸°¡ ÇÊ¿äÇϸç, 2022³â¿¡´Â 9¾ï 7õ¸¸ ¸íÀÌ »ç¸ÁÇϰí 5,350¸¸ ¸íÀÌ ¾Ï Áø´ÜÀ» ¹Þ°í »ì¾Æ°¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·ÐÀº PET ½ºÄµ¿¡ »ç¿ëµÇ´Â ¹æ»ç¼º µ¿À§¿ø¼Ò »ý»ê¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ´Ù¾çÇÑ À¯ÇüÀÇ ¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÏ´Â µ¥ ¸Å¿ì È¿°úÀûÀÔ´Ï´Ù. ¶ÇÇÑ ½ÉÇ÷°ü Áúȯ(CVD) ¹× ½Å°æ Áúȯ°ú °°Àº ¸¸¼º Áúȯ Áõ°¡·Î ÀÎÇØ Á¤¹Ð ¿µ»ó Áø´Ü ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀº Á¶±â Áø´Ü°ú È¿°úÀûÀÎ Ä¡·á °èȹÀ» Áß¿ä½ÃÇϱ⠶§¹®¿¡ ½Å·ÚÇÒ ¼ö ÀÖ´Â °íǰÁú ¹æ»ç¼º µ¿À§¿ø¼Ò¿¡ ´ëÇÑ ¼ö¿ä°¡ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¹æ»ç¼º ÀǾàǰÀÇ ¹ßÀü

¹æ»ç¼ºÀǾàǰÀº Áø´Ü°ú Ä¡·á ¸ñÀûÀ¸·Î ÇÙÀÇÇп¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù µé¾î º¸´Ù Á¤¹ÐÇϰí Ç¥ÀûÈ­µÈ ¹æ»ç¼ºÀǾàǰÀÌ °³¹ßµÇ¾î ¿µ»óÁø´Ü°ú Ä¡·áÀÇ Á¤È®¼º°ú À¯È¿¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹æ»ç¼ºÀǾàǰÀÇ ±â¼ú Çõ½ÅÀº ±× Àû¿ë ¹üÀ§¸¦ È®ÀåÇÏ¿© Á¾¾çÇлӸ¸ ¾Æ´Ï¶ó ¼øÈ¯±âÇÐ, ½Å°æÇÐ µî º¸´Ù ±¤¹üÀ§ÇÑ ÁúȯÀÇ Áø´Ü°ú Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹æ»ç¼ºÀǾàǰ ¿¬±¸¿¡ AI¿Í ¸Ó½Å·¯´×(ML)À» ÅëÇÕÇÏ¿© »õ·Î¿î È­ÇÕ¹° °³¹ß¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ȯÀÚ Ä¡·á °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº »õ·Î¿î ¹æ»ç¼º µ¿À§¿ø¼Ò »ý»ê¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ±Ô¸ð È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ÇコÄɾî ÀÎÇÁ¶ó È®´ë ¹× ¿µ»óÁø´Ü¿¡ ´ëÇÑ ÅõÀÚ

ÇコÄɾî ÀÎÇÁ¶óÀÇ È®´ë´Â ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. °ø°ø ±â°ü°ú ¹Î°£ ±â°ü ¸ðµÎ ÃÖ÷´Ü ¿µ»ó Áø´Ü Àåºñ¸¦ °®Ãá ÃÖ÷´Ü ÀÇ·á ½Ã¼³ °Ç¼³¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. º´¿ø ¹× Áø´Ü Ŭ¸®´ÐÀÇ PET ¹× PET-CT ¼¾ÅÍ ¼³Ä¡°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇÙÀÇÇÐ ¹× Áø´Ü À̹Ì¡À» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â°ú ÀÚ±Ý Áö¿øÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿©·¯ ±¹°¡¿¡¼­ ÷´Ü Áø´Ü µµ±¸¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϰí Çʼö ¹æ»ç¼º ÀǾàǰÀÇ Á¢±Ù¼ºÀ» º¸ÀåÇÏ´Â Á¤Ã¥À» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ¹æ»ç¼ºÀǾàǰÀº ÷´Ü ¿µ»óÁø´Ü¿¡ ÇÊ¿äÇÑ ¹æ»ç¼º µ¿À§¿ø¼Ò »ý»ê¿¡ ÇʼöÀûÀ̱⠶§¹®¿¡ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå Àü¸Á¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ¼¼ºÐÈ­ :

IMARC GroupÀº °¢ ½ÃÀå ºÎ¹®ÀÇ ÁÖ¿ä µ¿Ç⠺м®°ú 2024³âºÎÅÍ 2032³â±îÁö ¼¼°è, Áö¿ª ¹× ±¹°¡º° ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â ½ÃÀåÀ» À¯Çüº°, Á¦Ç° À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°·Î ºÐ·ùÇÕ´Ï´Ù.

À¯Çüº° ºÐ¼®

  • ¸µ »çÀÌŬ·ÎÆ®·Ð
  • ¹æÀ§°¢ °¡º¯ ÀÚ±âÀå(AVF) »çÀÌŬ·ÎÆ®·Ð

¸µ »çÀÌŬ·ÎÆ®·ÐÀÌ ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ½ÃÀåÀ» À¯Çüº°·Î »ó¼¼ÇÏ°Ô ºÐ·ùÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ¿©±â¿¡´Â ¸µ »çÀÌŬ·ÎÆ®·Ð°ú ¹æÀ§°¢ º¯µ¿ ÀÚ±âÀå(AVF) »çÀÌŬ·ÎÆ®·ÐÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼­¿¡ µû¸£¸é, ¸µ »çÀÌŬ·ÎÆ®·ÐÀÌ °¡Àå Å« ºÎ¹®À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ¾÷°è Åë°è¿¡ µû¸£¸é, ¸µ »çÀÌŬ·ÎÆ®·ÐÀº PET¿Í °°Àº ÷´Ü ¿µ»ó Áø´Ü ±â¼ú¿¡ ÇʼöÀûÀÎ °í¿¡³ÊÁö ¹æ»ç¼º µ¿À§¿ø¼Ò¸¦ »ý¼ºÇϴ Ź¿ùÇÑ ´É·ÂÀ¸·Î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¼³°è´Â ÀÔÀÚÀÇ ¿¬¼ÓÀûÀ̰í È¿À²ÀûÀÎ °¡¼ÓÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ´õ ³ôÀº ¼øµµ¿Í Àϰü¼ºÀ» °¡Áø ¹æ»ç¼º µ¿À§¿ø¼ÒÀÇ ³ôÀº ¼öÀ²À» ´Þ¼ºÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¸µ »çÀÌŬ·ÎÆ®·ÐÀº ±× È¿À²¼ºÀ¸·Î ÀÎÇØ ÀÇ·á ½Ã¼³¿¡¼­ ´ë·® »ý»ê¿¡ ÀûÇÕÇϸç, ÇʼöÀûÀÎ ¹æ»ç¼ºÀǾàǰÀÇ ¾ÈÁ¤ÀûÀÎ °ø±ÞÀ» º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ Ã·´Ü ±â¼úÀº º¸´Ù ±¤¹üÀ§ÇÑ µ¿À§¿ø¼Ò¸¦ Áö¿øÇÏ¿© ½ÉÀ庴ÇÐ, ½Å°æÇÐ µî Á¾¾çÇп¡ ±¹ÇѵÇÁö ¾Ê´Â ´Ù¾çÇÑ ÀÇ·á¿ëµµ¿¡ ´ëÀÀÇÕ´Ï´Ù. ³ôÀº »ý»ê ´É·Â, ½Å·Ú¼º, ´Ù¿ëµµ¼ºÀ» °âºñÇÑ ¸µ »çÀÌŬ·ÎÆ®·ÐÀº ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå¿¡¼­ ¼±Åùްí ÀÖ½À´Ï´Ù.

Á¦Ç° À¯Çüº° ºÐ·ù :

  • »çÀÌŬ·ÎÆ®·Ð 10-12 MeV
  • »çÀÌŬ·ÎÆ®·Ð 16-18 MeV
  • »çÀÌŬ·ÎÆ®·Ð 19-24 MeV
  • »çÀÌŬ·ÎÆ®·Ð 24MeV ÀÌ»ó

»çÀÌŬ·ÎÆ®·Ð 16-18MeV°¡ ¾÷°è ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡´Â Á¦Ç° À¯Çü¿¡ µû¸¥ ½ÃÀå ¼¼ºÐÈ­ ¹× ºÐ¼®µµ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â »çÀÌŬ·ÎÆ®·Ð 10-12MeV, »çÀÌŬ·ÎÆ®·Ð 16-18MeV, »çÀÌŬ·ÎÆ®·Ð 19-24MeV, »çÀÌŬ·ÎÆ®·Ð 24MeV ÀÌ»óÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼­¿¡ µû¸£¸é »çÀÌŬ·ÎÆ®·Ð 16-18MeV°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

16-18MeV ¿¡³ÊÁö ¼öÁØÀÇ »çÀÌŬ·ÎÆ®·Ð¿¡ ´ëÇÑ ¼ö¿ä´Â ÁÖ·Î »ý»ê ´É·Â°ú ¿î¿µ È¿À²¼ºÀÇ ÃÖÀû ±ÕÇü¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, PET À̹Ì¡¿¡ ÇʼöÀûÀÎ ºÒ¼Ò 18Àº ÀÌ·¯ÇÑ »çÀÌŬ·ÎÆ®·Ð¿¡¼­ »ý»êÇÒ ¼ö ÀÖ´Â ¸¹Àº ¹æ»ç¼º µ¿À§¿ø¼Ò Áß ÇϳªÀÔ´Ï´Ù. ¿¡³ÊÁö ¹üÀ§´Â ´ëÇü º´¿ø°ú »ó¾÷¿ë ¹æ»ç¼º ¾à±¹ ¼ö¿ä¸¦ ÃæÁ·½ÃŰ±â¿¡ ÃæºÐÇÑ ¼öÀ²·Î °í¼øµµ µ¿À§¿ø¼Ò¸¦ È¿À²ÀûÀ¸·Î »ý»êÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¶ÇÇÑ, ÀÌ »çÀÌŬ·ÎÆ®·ÐÀº ºñ¿ë È¿À²ÀûÀ̸ç ÀÇ·á ½Ã¼³¿¡ À¯¸®ÇÑ ÅõÀÚ ¼öÀÍ·üÀ» Á¦°øÇÕ´Ï´Ù. 16-18MeV »çÀÌŬ·ÎÆ®·ÐÀº ´Ù¾çÇÑ Áø´Ü ¹× Ä¡·á ¿ëµµ¸¦ Áö¿øÇÏ´Â ´É·Â°ú °áÇÕµÈ ´ÙÀç´Ù´ÉÇÔÀ¸·Î ÀÎÇØ ¾÷°è¿¡¼­ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº° ºÐ¼®

  • º´¿ø
  • Áø´Ü¼¾ÅÍ
  • ¿¬±¸ ¹× Çмú±â°ü
  • ±âŸ

º´¿øÀÌ ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®À» Â÷ÁöÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÃÖÁ¾ »ç¿ëÀÚº°·Î ½ÃÀåÀ» ¼¼ºÎÀûÀ¸·Î ºÐ·ùÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ¿©±â¿¡´Â º´¿ø, Áø´Ü¼¾ÅÍ, ¿¬±¸ ¹× Çмú ±â°ü, ±âŸ µîÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼­¿¡ µû¸£¸é, º´¿øÀÌ °¡Àå Å« ºÎ¹®À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é º´¿øÀÌ °¡Àå Å« ÃÖÁ¾ »ç¿ëÀÚÀÌ¸ç °í±Þ Áø´Ü ¹× Ä¡·á ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. º´¿ø ³» ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·ÐÀº PET ¹× SPECT À̹Ì¡¿¡ »ç¿ëµÇ´Â Çʼö ¹æ»ç¼º µ¿À§¿ø¼Ò¸¦ »ý¼ºÇÕ´Ï´Ù. ÀÌ´Â ¾Ï, CVD, ½Å°æÁúȯ µî ´Ù¾çÇÑ Áúº´ÀÇ Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. »çÀÌŬ·ÎÆ®·ÐÀ» º´¿ø ³»¿¡ ¼³Ä¡Çϸé ÀÌ·¯ÇÑ ¹æ»ç¼ºÀǾàǰÀ» Àû½Ã¿¡ ¾ÈÁ¤ÀûÀ¸·Î °ø±ÞÇÒ ¼ö ÀÖ¾î ȯÀÚ Ä¡·á¿Í Ä¡·á °á°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹æ»ç¼º µ¿À§¿ø¼Ò ÀÚü »ý»ê Áõ°¡ Ãß¼¼¿¡ µû¶ó º´¿øÀº ¿ÜºÎ °ø±Þ¾÷ü¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙÀÌ°í ¿î¿µ ºñ¿ëÀ» Àý°¨Çϸç ÇÙÀÇÇÐ ºÎ¼­ÀÇ È¿À²¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

Áö¿ªº° ºÐ¼®

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿/¾ÆÇÁ¸®Ä«

¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ºÏ¹Ì(¹Ì±¹, ij³ª´Ù), À¯·´(µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ·¯½Ã¾Æ, ±âŸ), ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, Çѱ¹, È£ÁÖ, Àεµ³×½Ã¾Æ, ±âŸ), ¶óƾ¾Æ¸Þ¸®Ä«(ºê¶óÁú, ¸ß½ÃÄÚ, ±âŸ), Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« µî ÁÖ¿ä Áö¿ª ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. º¸°í¼­¿¡ µû¸£¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·ÐÀÇ °¡Àå ±Ô¸ð°¡ Å« Áö¿ª ½ÃÀåÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ºÐ¼®¿¡ µû¸£¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ƯÈ÷ Áß±¹, ÀϺ», Àεµ¿Í °°Àº ±¹°¡¿¡¼­ źźÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë·Î ÀÎÇØ ÷´Ü Áø´Ü ¹× Ä¡·á ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ÁÖ¿ä Áö¿ªÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ÅõÀÚ Áõ°¡¿Í À¯¸®ÇÑ Á¤Ã¥Àº ÀÇ·á ½Ã¼³¿¡¼­ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·ÐÀÇ Ã¤ÅÃÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ª¿¡¼­ ¾Ï ¹× ±âŸ ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °í±Þ ¿µ»ó Áø´Ü ¹× Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä »çÀÌŬ·ÎÆ®·Ð Á¦Á¶¾÷üÀÇ Á¸Àç¿Í ÇÙÀÇÇÐ ¿¬±¸ ¹× °³¹ß(R&D)ÀÌ È°¹ßÈ÷ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ÀÌ Áö¿ªÀÇ °­Á¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

(Âü°í·Î, ÀÌ´Â ÁÖ¿ä ±â¾÷ÀÇ ÀϺΠ¸ñ·ÏÀ̸ç, Àüü ¸ñ·ÏÀº º¸°í¼­¿¡¼­ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù)

  • ¼¼°è °æÀï ȯ°æÀº °æÀï ¿ìÀ§¸¦ È®º¸Çϱâ À§ÇØ ²÷ÀÓ¾øÀÌ Çõ½ÅÇÏ´Â ¿©·¯ ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç·Î Ư¡Áö¾îÁý´Ï´Ù. Á¦Á¶¾÷üµéÀº ±¤¹üÀ§ÇÑ Á¦Ç° Æ÷Æ®Æú¸®¿À, ±â¼ú ¹ßÀü, °­·ÂÇÑ ÆÇ¸Å¸ÁÀ» ÅëÇØ ½ÃÀåÀ» Àå¾ÇÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ¾÷°è ¸®´õµéÀº ´õ ³ôÀº È¿À²¼º, ½Å·Ú¼º, ¾ÈÀü¼ºÀ» °®Ãá ÷´Ü »çÀÌŬ·ÎÆ®·Ð ¸ðµ¨À» µµÀÔÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÆÄÆ®³Ê½Ê, ÇÕº´ ¹× Àμö´Â ½ÃÀå µµ´Þ ¹üÀ§¸¦ È®ÀåÇÏ°í ¿ª·®À» °­È­Çϱâ À§ÇØ Ã¤ÅÃÇÏ´Â ÀϹÝÀûÀÎ Àü·«ÀÔ´Ï´Ù. ½ÅÈï ±â¾÷¿Í Áö¿ª Á¦Á¶¾÷üµéµµ Áö¿ª ½ÃÀåÀÇ ¿ä±¸¿¡ ¸Â´Â ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á Å« ÁøÀüÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í »õ·Î¿î ¹æ»ç¼ºÀǾàǰÀÇ °³¹ßÀº Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ´Â ÀÇ·áÁø°ú ȯÀÚµéÀÇ ¿ä±¸¿¡ ºÎÀÀÇϱâ À§ÇÑ ±â¾÷µéÀÇ ³ë·Â°ú ÇÔ²² ½ÃÀåÀÇ °æÀï°ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ´º½º:

  • 2024³â 3¿ù, Á¤¹ÐÀÇ·áÀÇ ¼±µÎÁÖÀÚÀÎ GEÇコÄɾî´Â GE±×·ì¿¡¼­ µ¶¸³ÇÏ¿© 1¿ù¿¡ ³ª½º´Ú¿¡ »óÀåÇß½À´Ï´Ù. ÀÌ È¸»ç´Â ÀÇ·á ¿µ»ó, ÃÊÀ½ÆÄ, ¶óÀÌÇÁ Äɾî, Á¦¾à °øµ¿ Áø´Ü ºÐ¾ß¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • 2023³â ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ¼¼°è ½ÃÀå ¼ºÀå·üÀº?
  • ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ¼¼°è ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • Äڷγª19°¡ ¼¼°è ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀåÀÇ À¯Çüº° ºÐ·ù´Â?
  • ¼¼°è ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀåÀÇ Á¦Ç° À¯Çüº° ºÐ·ù´Â?
  • ¼¼°è ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀåÀÇ ÃÖÁ¾ »ç¿ëÀÚº° ºÐ¼®Àº?
  • ¼¼°è ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº ¾îµðÀΰ¡?
  • ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ¼¼°è ½ÃÀå¿¡¼­ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : À¯Çüº°

  • ¸µ »çÀÌŬ·ÎÆ®·Ð
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¹æÀ§°¢ °¡º¯ ÀÚÀå(AVF) »çÀÌŬ·ÎÆ®·Ð
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ºÐ¼® : Á¦Ç° À¯Çüº°

  • »çÀÌŬ·ÎÆ®·Ð10-12 MeV
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • »çÀÌŬ·ÎÆ®·Ð16-18 MeV
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • »çÀÌŬ·ÎÆ®·Ð19-24 MeV
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • »çÀÌŬ·ÎÆ®·Ð 24 MeV ÀÌ»ó
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Áø´Ü¼¾ÅÍ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¿¬±¸ ¹× Çмú±â°ü
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå PorterÀÇ Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Advanced Cyclotron Systems Inc.
    • Alcen
    • Best Medical International Inc.
    • General Electric Company
    • IBA RadioPharma Solutions
    • Ionetix Corporation
    • Isosolution Inc.
    • Siemens AG
    • Sumitomo Heavy Industries Ltd.
    • Varian Medical Systems Inc.
LSH 24.10.17

The global medical cyclotron market size reached US$ 230.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 453.4 Million by 2032, exhibiting a growth rate (CAGR) of 7.6% during 2024-2032. The increasing cancer prevalence, advancements in radiopharmaceuticals, rising demand for positron emission tomography (PET) scans, technological innovations, expanding healthcare infrastructure, growing research activities, and supportive government initiatives promoting nuclear medicine and diagnostic imaging are some of the key factors strengthening the market growth.

Medical Cyclotron Market Analysis:

  • Major Market Drivers: The demand for medical cyclotrons to generate necessary radioisotopes for cutting-edge diagnostic imaging methods such as PET and single photon emission computed tomography (SPECT) combined with the burgeoning incidence of cancer and chronic diseases worldwide is impelling the market growth. In line with this, ongoing technological advancements in cyclotron design and efficiency enhance production capabilities and reduce operational costs, fueling market expansion.
  • Key Market Trends: Some of the major medical cyclotron market trends include developments in the field of radiopharmaceuticals, such as the creation of novel compounds and their incorporation with artificial intelligence (AI), which improve treatment efficacy and diagnostic precision while also increasing the demand for sophisticated cyclotrons.
  • Geographical Trends: Asia Pacific leads the market with its robust healthcare infrastructure growth, significant government investments, and a high prevalence of chronic diseases in countries like China, Japan, and India. Meanwhile, North America and Europe also hold substantial medical cyclotron market share, driven by advanced healthcare systems, strong R&D activities, and the presence of major cyclotron manufacturers.
  • Competitive Landscape: Some of the major market players in the medical cyclotron industry include Advanced Cyclotron Systems Inc., Alcen, Best Medical International Inc., General Electric Company, IBA RadioPharma Solutions, Ionetix Corporation, Isosolution Inc., Siemens AG, Sumitomo Heavy Industries Ltd., Varian Medical Systems Inc, among many others.
  • Challenges and Opportunities: High initial costs and complex regulatory requirements for cyclotron installation and operation pose challenges for market entry and expansion. Meanwhile, the business opportunity lies in the growing demand for portable and lower-cost cyclotron models with limited healthcare infrastructure. Moreover, the creation of novel radiopharmaceuticals and the growing emphasis on precision medicine present enormous growth prospects for cyclotron producers to innovate and broaden their range of products.

Medical Cyclotron Market Trends:

Rising prevalence of cancer and chronic diseases

Medical cyclotron market research report shows that one of the primary trends driving the market is the increasing incidence of cancer and other chronic diseases worldwide. Cancer remains one of the leading causes of death globally, necessitating advanced diagnostic tools for early detection and treatment. In 2022, there were 9.7 million deaths and 53.5 million living with a cancer diagnosis. Medical cyclotrons play a crucial role in producing radioisotopes used in PET scans, which are highly effective in detecting various types of cancers at an early stage. Additionally, the escalating prevelance of chronic diseases such as cardiovascular disorders (CVD) and neurological conditions has increased the demand for precise diagnostic imaging techniques. As healthcare systems emphasize early diagnosis and effective treatment plans, the need for reliable and high-quality radioisotopes is bolstering the medical cyclotron market growth.

Advancements in radiopharmaceuticals

Radiopharmaceuticals play a crucial role in nuclear medicine for both diagnostic and therapeutic purposes. Recent advancements have led to the development of more precise and targeted radiopharmaceuticals, enhancing the accuracy and effectiveness of diagnostic imaging and treatments. This innovation in radiopharmaceuticals has expanded their application scope, enabling the diagnosis and treatment of a broader range of diseases beyond oncology, including cardiology and neurology. Moreover, the integration of AI and machine learning (ML) in radiopharmaceutical research has spurred the development of new compounds, improving patient outcomes. These advancements necessitate the production of novel radioisotopes, thereby providing an impetus to the medical cyclotron market size.

Expanding healthcare infrastructure and investments in diagnostic imaging

The expansion of healthcare infrastructure significantly contributes to the market growth. Both public and private organizations are making significant investments in the construction of cutting-edge medical facilities outfitted with cutting-edge diagnostic imaging equipment. The increasing establishment of PET and PET-CT centers in hospitals and diagnostic clinics is aiding in market expansion. Moreover, favorable government initiatives and funding to promote nuclear medicine and diagnostic imaging are further supporting the market growth. For instance, various countries are implementing policies to improve access to advanced diagnostic tools and ensure the availability of essential radiopharmaceuticals. This is positively impacting the medical cyclotron market outlook because they are essential for producing the radioisotopes needed for these cutting-edge imaging methods.

Medical Cyclotron Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, product type, and end user.

Breakup by Type:

  • Ring Cyclotron
  • Azimuthally Varying Field (AVF) Cyclotron

Ring cyclotron accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes ring cyclotron and azimuthally varying field (AVF) cyclotron. According to the report, ring cyclotron represented the largest segment.

As per the medical cyclotron industry statistics, ring cyclotrons dominate the market due to their superior capabilities in producing high-energy radioisotopes essential for advanced diagnostic imaging techniques like PET. Their design allows for continuous and efficient acceleration of particles, resulting in higher yields of radioisotopes with greater purity and consistency. Ring cyclotrons are well-suited for large-scale production in medical facilities owing to their efficiency, which guarantees a consistent supply of essential radiopharmaceuticals. Additionally, their advanced technology supports a wider range of isotopes, catering to diverse medical applications beyond oncology, such as cardiology and neurology. The combination of high production capacity, reliability, and versatility positions ring cyclotrons as the preferred choice in the medical cyclotron market.

Breakup by Product Type:

  • Cyclotron 10-12 MeV
  • Cyclotron 16-18 MeV
  • Cyclotron 19-24 MeV
  • Cyclotron 24 MeV and Above

Cyclotron 16-18 MeV holds the largest share of the industry

A detailed breakup and analysis of the market based on the product type have also been provided in the report. This includes cyclotron 10-12 MeV, cyclotron 16-18 MeV, cyclotron 19-24 MeV, and cyclotron 24 MeV and above. According to the report, cyclotron 16-18 MeV accounted for the largest market share.

The demand for cyclotrons with 16-18 MeV energy levels is mainly driven by their optimal balance between production capacity and operational efficiency. Fluorine-18, which is essential for PET imaging, is among the many radioisotopes that can be produced by these cyclotrons. The 16-18 MeV energy range allows for efficient production of high-purity isotopes with sufficient yield to meet the demands of both large hospitals and commercial radio pharmacies. Additionally, these cyclotrons are cost-effective, offering a favorable return on investment for medical facilities. Their versatility, combined with the ability to support diverse diagnostic and therapeutic applications, makes 16-18 MeV cyclotrons the preferred choice in the industry.

Breakup by End User:

  • Hospitals
  • Diagnostic Centers
  • Research and Academic Institutes
  • Others

Hospitals represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostic centers, research and academic institutes, and others. According to the report, hospitals represented the largest segment.

Medical cyclotron market insights exhibit hospitals as the biggest end users with their critical role in providing advanced diagnostic and therapeutic services. Medical cyclotrons in hospitals produce essential radioisotopes used in PET and SPECT imaging, which are pivotal for diagnosing and monitoring various diseases, including cancer, CVDs, and neurological disorders. The integration of cyclotrons within hospital settings ensures a timely and reliable supply of these radiopharmaceuticals, enhancing patient care and treatment outcomes. Furthermore, the growing trend of in-house production of radioisotopes allows hospitals to reduce dependence on external suppliers, lower operational costs, and improve the efficiency of their nuclear medicine departments.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Asia Pacific leads the market, accounting for the largest medical cyclotron market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific represents the largest regional market for medical cyclotron.

Medical cyclotron market analysis revealed Asia Pacific as the leading region due to robust healthcare infrastructure expansion, particularly in countries like China, Japan, and India, which boosts the demand for advanced diagnostic and therapeutic technologies. Increasing government investments and favorable policies support the adoption of medical cyclotrons in healthcare facilities. Additionally, the rising prevalence of cancer and other chronic diseases in the region amplifies the need for advanced imaging and treatment solutions, further driving market growth. The presence of leading cyclotron manufacturers and growing research and development (R&D) activities in nuclear medicine also contribute to the region's dominance.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the medical cyclotron industry include Advanced Cyclotron Systems Inc., Alcen, Best Medical International Inc., General Electric Company, IBA RadioPharma Solutions, Ionetix Corporation, Isosolution Inc., Siemens AG, Sumitomo Heavy Industries Ltd., Varian Medical Systems Inc, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The competitive landscape of the global medical cyclotron market is characterized by the presence of several key players who are constantly innovating to gain a competitive edge. Manufacturers dominate the market due to their extensive product portfolios, technological advancements, and strong distribution networks. These industry leaders invest heavily in R&D to introduce advanced cyclotron models with higher efficiency, reliability, and safety features. Additionally, partnerships, mergers, and acquisitions are common strategies employed to expand market reach and enhance capabilities. Emerging players and regional manufacturers are also making significant strides by offering cost-effective solutions tailored to local market needs. Besides this, the increasing demand for personalized medicine and the development of new radiopharmaceuticals are driving further competition and innovation in the market as companies strive to meet the growing needs of healthcare providers and patients globally.

Medical Cyclotron Market News:

  • In March 2024, GE HealthCare, a leader in precision medicine, became an independent entity from GE Group and was listed on NASDAQ in January. The company operates across medical imaging, ultrasound, life care, and pharma co-diagnosis.

Key Questions Answered in This Report

  • 1. What was the size of the global medical cyclotron market in 2023?
  • 2. What is the expected growth rate of the global medical cyclotron market during 2024-2032?
  • 3. What are the key factors driving the global medical cyclotron market?
  • 4. What has been the impact of COVID-19 on the global medical cyclotron market?
  • 5. What is the breakup of the global medical cyclotron market based on the type?
  • 6. What is the breakup of the global medical cyclotron market based on the product type?
  • 7. What is the breakup of the global medical cyclotron market based on the end user?
  • 8. What are the key regions in the global medical cyclotron market?
  • 9. Who are the key players/companies in the global medical cyclotron market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Medical Cyclotron Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Ring Cyclotron
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Azimuthally Varying Field (AVF) Cyclotron
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Cyclotron 10-12 MeV
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cyclotron 16-18 MeV
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cyclotron 19-24 MeV
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cyclotron 24 MeV and Above
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostic Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research and Academic Institutes
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Advanced Cyclotron Systems Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Alcen
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Best Medical International Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 General Electric Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 IBA RadioPharma Solutions
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Ionetix Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Isosolution Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Siemens AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sumitomo Heavy Industries Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Varian Medical Systems Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦